Clinical Trial

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Study acronym: EX-BOOST
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, and ii) preliminary data on the impact of a day-of-therapy exercise intervention.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-18; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2026-03-24
Status change: Not Yet Recruiting → Recruiting 2023-11-06
Trial Details
NCT Number NCT06008977
Lead Sponsor AdventHealth Translational Research Institute
Conditions Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
Enrollment 12 participants
Start Date 2024-06-03
Primary Completion 2025-08-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-25